Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.

78 Interim results from a phase II study presented at the European Hematology Association Congress in 2019 showed a trend toward increased HbF and reduced hemolysis and cellular adhesion factors in SCD patients treated with IMR-687 100 mg orally once a day. 79 cGMP-amplifying agents have been shown to intensify the nitric oxide-mediated effects of HU in animal models. 22 As a result, it is possible that all of these agents may act synergistically with HU.

also in 53,322 other papers